ICAM1-DM1

ICAM1-DM1 is a rationally designed antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting Intercellular Adhesion Molecule 1 (ICAM1) conjugated to the cytotoxic agent mertansine (DM1) via a stable non-cleavable linker (SMCC). The ADC is designed to selectively bind to ICAM1, which is highly overexpressed on the surface of human pancreatic cancer (PC) cells (and overexpressed in other cancers such as triple-negative breast cancer, melanoma, and thyroid cancer), but shows limited expression in most normal tissues. Upon binding, the conjugate is internalized and DM1 (a microtubule inhibitor) is released inside the cancer cell, leading to cell cycle arrest and apoptosis. Preclinical studies have demonstrated that ICAM1-DM1 has potent and selective antitumor activity against human pancreatic cancer cells in vitro and in mouse xenograft models, with significantly reduced off-target toxicity. The ADC may also be monitored and optimized using MRI-based companion imaging to evaluate ICAM1 expression and predict therapeutic response[1][2][3][4].

Other names

ICAM1 antibody-drug conjugate DM1ICAM-1 antibody-drug conjugate DM1ICAM 1 antibody-drug conjugate DM1ICAM1-SMCC-DM1ICAM-1-SMCC-DM1ICAM 1-SMCC-DM1